Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valproic acid
Drug ID BADD_D02329
Description Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Indications and Usage For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.
Marketing Status Prescription; Discontinued
ATC Code N03AG01
DrugBank ID DB00313
KEGG ID D00399
MeSH ID D014635
PubChem ID 3121
TTD Drug ID D03LGY
NDC Product Code 0591-4012; 17856-0152; 63629-2454; 72189-267; 60432-621; 0121-4675; 72189-010; 43353-085; 17349-0005; 68108-0203; 71930-057; 69452-150; 62756-920; 66064-8001; 17856-0675; 11014-0054; 0121-1350; 0615-8205; 68094-701; 43353-107; 10888-8132; 11014-0050; 70518-0079; 63739-253; 70518-0730; 42291-844; 0832-0310; 23639-0003; 50383-792; 68094-193; 0121-0675; 0527-5250; 49452-8092; 63739-086; 68925-0002; 43353-279; 63629-7597; 60687-262
Synonyms Valproic Acid | 2-Propylpentanoic Acid | 2 Propylpentanoic Acid | Divalproex | Depakene | Convulsofin | Depakote | Dipropyl Acetate | Divalproex Sodium | Semisodium Valproate | Vupral | Valproic Acid, Sodium Salt (2:1) | Propylisopropylacetic Acid | Ergenyl | Magnesium Valproate | Valproate | Valproate Sodium | Sodium Valproate | Calcium Valproate | Valproate Calcium | Depakine
Chemical Information
Molecular Formula C8H16O2
CAS Registry Number 99-66-1
SMILES CCCC(CCC)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 1A2P05177Not AvailableNot Available
HepatotoxicityCytochrome P450 2E1P05181Not AvailableNot Available
HepatotoxicityCytochrome P450 2C9P11712T19244Not Available
HepatotoxicityCytochrome P450 2A6P11509T06455Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness neurosensory17.04.07.001; 04.02.01.0020.000443%Not Available
Death08.04.01.001--
Death neonatal18.04.01.002; 08.04.01.0020.000404%
Decreased activity19.11.01.002; 08.01.01.0060.000443%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.004207%
Delusion19.10.01.0010.000886%
Dementia19.20.02.001; 17.03.01.0010.001993%Not Available
Depressed level of consciousness17.02.04.0020.006422%
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000664%Not Available
Dermatitis bullous23.03.01.0020.000664%
Developmental coordination disorder19.22.01.001; 17.02.02.0110.000231%Not Available
Developmental delay08.01.03.0370.022144%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000116%Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.001107%Not Available
Disinhibition19.05.01.0020.000443%Not Available
Disorientation17.02.05.015; 19.13.01.0020.004429%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000173%
Dissociation19.14.01.0020.000443%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.003765%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug abuse19.07.02.010--Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000664%Not Available
Drug hypersensitivity10.01.01.001--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 30 Pages